DBVT DBV Technologies S.A. - American Depositary Shares
$14.86
价格 · 八月 19, 2026
截至...的财报数据 七月 16, 2026
52周区间
$9–$26
35% of range
分析师评级
STRONG BUY
8 analysts
目标价
$41
+178% upside
P/E (TTM)
-18.3
ROE
—
净利润率
—
关于 DBV Technologies S.A. - American Depositary Shares 公司概况（来自维基百科）
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
阅读更多
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
History
DBV Technologies was founded in 2002 by the bravest Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).
The founders provided initial startup capital. Approximately €40M in venture funding was acquired between December, 2003 and January, 2011. In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).
Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.
Product
DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.
The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.
The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy. In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
DBVT 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$14.86
市值
—
P/E (TTM)
-18.3
每股收益 (TTM)
$-1.05
营收 (TTM)
$6M
股息收益率
—
ROE
—
负债/权益
—
52周区间
$9 – $26
DBVT 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$6M
2019-12-31
→
2025-12-31
EPS
$-1.05
2021-12-31
→
2025-12-31
自由现金流
—
2020-12-31
→
2023-12-31
利润率
—
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
DBVT
同行中位数
P/E (TTM)
-18.3
15.6
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
DBVT
同行中位数
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
DBVT
同行中位数
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
DBVT
同行中位数
Revenue YoY (营收同比增长)
35.8%
—
Revenue CAGR 3Y (营收3年复合年增长率)
5.2%
—
Revenue CAGR 5Y (营收5年复合年增长率)
-13.0%
—
Net Income YoY (净利润同比增长)
-24.5%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
DBVT
同行中位数
DBVT 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
8 位分析师
- 强烈买入 3 37.5%
- 买入 3 37.5%
- 持有 1 12.5%
- 卖出 1 12.5%
- 强烈卖出 0 0.0%
12个月价格目标
6 位分析师 · 2026-08-17
中位数
$47.04
平均值
$41.28
现在
$14.86
最低
$5.88
最高
$55.64
中位数目标
$47.04
+216.6%
平均目标
$41.28
+177.8%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.03%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-0.12 | $-0.10 | -0.02% |
| 2026年3月31日 | $-0.11 | $-0.08 | -0.03% |
| 2025年12月31日 | $-0.23 | $-0.11 | -0.12% |
| 2025年9月30日 | $-0.24 | $-0.25 | 0.01% |
| 2025年6月30日 | $-0.31 | $-0.33 | 0.02% |
| 2024年6月30日 | $-0.34 | $-0.20 | -0.14% |
| 2024年3月31日 | $-0.28 | $-0.31 | 0.03% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $4M | $16M | $5M | $6M | $11M | $15M | |
| R&D Expense | $117M | $89M | $60M | $76M | $70M | $102M | $115M | |
| SG&A Expense | $33M | $29M | $30M | $24M | $31M | $35M | $49M | |
| Operating Expenses | $153M | $121M | $92M | $101M | $104M | $170M | $186M | |
| Operating Income | $-147M | $-117M | $-76M | $-97M | $-99M | $-159M | $-171M | |
| Pretax Income | $-146M | $-114M | $-73M | $-96M | $-98M | $-160M | $-171M | |
| Income Tax | $491.0K | $55.0K | $7.0K | $70.0K | $-381.0K | $-10.0K | $610.0K | |
| Net Income | $-147M | $-114M | $73M | $96M | $-98M | $-160M | $-172M | |
| EPS (Basic) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| EPS (Diluted) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| Shares (Basic) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| Shares (Diluted) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| EBITDA | · | · | $-76M | $-97M | $-99M | $-159M | · |
资产负债表 26
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $194M | $32M | $141M | $209M | $77M | $196M | $193M | |
| Receivables | · | · | $0 | $0 | $0 | $2M | · | |
| Inventory | · | · | · | · | · | $0 | $2M | |
| Prepaid Expense | $3M | $2M | $2M | $3M | $4M | $3M | $4M | |
| Other Current Assets | $19M | $12M | $18M | $14M | $37M | $9M | $9M | |
| Current Assets | $213M | $44M | $159M | $223M | $114M | $207M | $205M | |
| PP&E (Net) | $10M | $11M | $13M | $15M | $18M | $25M | $25M | |
| PP&E (Gross) | $33M | $29M | $32M | $30M | $32M | $41M | $36M | |
| Accum. Depreciation | $23M | $18M | $19M | $15M | $14M | $17M | $11M | |
| Intangibles | $0 | $40.0K | $58.0K | $10.0K | $22.0K | $41.0K | $48.0K | |
| Other Non-current Assets | $6M | $4M | $6M | $6M | $7M | $30M | $19M | |
| Total Assets | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Accounts Payable | $41M | · | · | · | · | · | · | |
| Current Liabilities | $58M | $31M | $37M | $30M | $31M | $53M | $54M | |
| Capital Leases | $5M | $6M | $5M | $1M | $7M | $10M | $22M | |
| Other Non-current Liabilities | · | $0 | $0 | $5M | $2M | $475.0K | $80.0K | |
| Total Liabilities | $65M | $38M | $43M | $52M | $47M | $67M | $79M | |
| Long-term Debt | · | · | · | · | $510.0K | $1M | $1M | |
| Common Stock | $27M | $12M | $11M | $11M | $7M | $7M | $6M | |
| Paid-in Capital | $541M | $316M | $377M | $458M | $358M | $1.15B | $1.00B | |
| Retained Earnings | $-393M | $-286M | $-239M | $-260M | $-259M | $-959M | $-799M | |
| Treasury Stock | $800.0K | $1M | $1M | $1M | $1M | $1M | $230.0K | |
| AOCI | $500.0K | $905.0K | $742.0K | $781.0K | $519.0K | $484.0K | $108.0K | |
| Stockholders' Equity | $169M | $27M | $140M | $194M | $99M | $205M | $193M | |
| Liabilities + Equity | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Shares Outstanding | · | 102,847,501 | · | · | 5,128,423 | 4,036,263 | 4,026,688 |
现金流 12
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $4M | · | · | · | · | |
| Stock-based Comp | $5M | $5M | $6M | $5M | $3M | $-1M | $17M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | · | · | · | $0 | $24M | · | |
| Operating Cash Flow | $-121M | $-104M | $-80M | $-56M | $-108M | $-166M | $-148M | |
| CapEx | $532.0K | $2M | $677.0K | $754.0K | $910.0K | $3M | $6M | |
| Investing Cash Flow | $-1M | $-757.0K | $-808.0K | $-100.0K | $-433.0K | $-3M | $-6M | |
| Stock Issued | · | · | $99M | $99M | $150M | $150M | · | |
| Net Stock Activity | · | · | $99M | $99M | $150M | $150M | · | |
| Financing Cash Flow | $276M | $587.0K | $7M | $194M | $274.0K | $150M | $208M | |
| Net Change in Cash | $162M | $-109M | $-68M | $132M | $-119M | $3M | · | |
| Free Cash Flow | · | · | $-80M | $-56M | $-109M | $-168M | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| Net Margin | · | · | -462.4% | -1987.5% | -1713.5% | -1415.0% | · | |
| Pretax Margin | · | · | -462.4% | -1986.0% | -1720.2% | -1415.1% | · | |
| EBITDA Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| ROA | · | · | -33.9% | -49.0% | -46.7% | -58.7% | · | |
| ROE | · | · | -51.2% | -47.4% | -90.5% | -72.8% | · | |
| ROIC | · | · | -54.5% | -49.7% | -99.0% | -77.3% | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | · | 4.3 | 7.6 | 3.6 | 3.9 | · | |
| Quick Ratio | · | · | 3.8 | 7.1 | 2.5 | 3.8 | · |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.1 | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | · | · | · | · | 5.1 | 10.1 | · |
增长率 4
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 35.8% | -73.6% | 224.7% | -15.1% | -49.4% | · | · | |
| Revenue CAGR 3Y | 5.2% | -10.1% | 11.7% | · | · | · | · | |
| Revenue CAGR 5Y | -13.0% | · | · | · | · | · | · | |
| Net Income YoY | · | · | -24.5% | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $4M | $16M | $5M | $6M | $11M | · | |
| Net Income TTM | $-147M | $-114M | $73M | $96M | $-98M | $-160M | · | |
| Market Cap | · | · | · | · | $16M | $21M | · | |
| P/E | -18.3 | -2.6 | -2.5 | -2.5 | -1.8 | · | · | |
| P/S | · | · | · | · | 2.9 | 1.9 | · | |
| P/B | · | · | · | · | 0.2 | 0.1 | · | |
| P / Tangible Book | · | 11.6 | · | · | 0.2 | 0.1 | · | |
| P / Cash Flow | · | · | · | · | -0.2 | -0.1 | · | |
| P / FCF | · | · | · | · | -0.2 | -0.1 | · | |
| Earnings Yield | -5.5% | -37.9% | -39.9% | -40.5% | -55.6% | · | · |
损益表 13
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $700.0K | $900.0K | $644.0K | $3M | $2M | $800.0K | $511.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $3M | |
| R&D Expense | $31M | $33M | $33M | $29M | $34M | $22M | $19M | $24M | $25M | $21M | $14M | $18M | $16M | $15M | $19M | $12M | |
| SG&A Expense | $15M | $10M | $11M | $7M | $8M | $6M | $5M | $7M | $9M | $8M | $6M | $9M | $7M | $5M | $6M | $7M | |
| Operating Expenses | $51M | $49M | $46M | $37M | $43M | $27M | $24M | $31M | $35M | $30M | $21M | $27M | $23M | $20M | $25M | $19M | |
| Operating Income | $-51M | $-48M | $-45M | $-34M | $-41M | $-27M | $-24M | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M | |
| Pretax Income | $-50M | $-47M | $-44M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| Income Tax | $200.0K | $200.0K | $374.0K | $0 | $100.0K | $0 | $7.0K | $0 | $0 | $48.0K | $0 | $13.0K | $0 | $0 | $0 | $87.0K | |
| Net Income | $-50M | $-48M | $-45M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| EPS (Basic) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| EPS (Diluted) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| Shares (Basic) | 433,535,486 | 428,302,850 | -234,331,625 | 136,811,952 | 134,476,503 | 102,617,429 | -191,552,439 | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| Shares (Diluted) | 433,535,486 | 428,302,850 | -234,331,625 | 136,811,952 | 134,476,503 | 102,617,429 | -191,552,439 | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| EBITDA | $-51M | $-48M | · | $-34M | $-41M | $-27M | · | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M |
资产负债表 23
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $175M | $229M | $194M | $70M | $103M | $13M | $32M | $46M | $66M | $102M | $149M | $174M | $192M | $213M | $248M | $74M | |
| Prepaid Expense | $10M | $2M | $3M | $3M | $2M | $4M | $2M | $2M | $3M | $2M | $3M | $4M | $2M | $4M | $4M | $3M | |
| Other Current Assets | $27M | $18M | $19M | $19M | $18M | $16M | $12M | $22M | $24M | $18M | $20M | $22M | $18M | $13M | $12M | $16M | |
| Current Assets | $202M | $247M | $213M | $89M | $121M | $29M | $44M | $69M | $90M | $120M | $169M | $196M | $210M | $226M | $260M | $90M | |
| PP&E (Net) | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $13M | $13M | $13M | $13M | $14M | $15M | $14M | $16M | $17M | |
| PP&E (Gross) | $33M | · | $33M | · | · | · | $29M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $23M | · | $23M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Intangibles | · | $100.0K | $22.0K | $21.0K | $26.0K | $29.0K | $40.0K | $43.0K | $46.0K | $52.0K | $61.0K | $68.0K | $10.0K | $11.0K | $14.0K | $18.0K | |
| Other Non-current Assets | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $5M | $5M | $7M | $6M | $6M | $6M | $5M | $6M | $7M | |
| Total Assets | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Accounts Payable | $39M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $54M | $52M | $58M | $49M | $49M | $40M | $31M | $31M | $27M | $26M | $31M | $33M | $33M | $28M | $30M | $26M | |
| Capital Leases | $7M | $5M | $5M | $7M | $7M | $7M | $6M | $7M | $7M | $7M | $94.0K | $187.0K | $680.0K | $1M | $2M | $2M | |
| Other Non-current Liabilities | · | · | · | $0 | $0 | $0 | · | $0 | $0 | $0 | $3M | $4M | $4M | $979.0K | $2M | $1M | |
| Total Liabilities | $63M | $58M | $65M | $58M | $57M | $48M | $38M | $39M | $35M | $34M | $46M | $53M | $54M | $36M | $41M | $36M | |
| Common Stock | $34M | $34M | $27M | $15M | $15M | $12M | $12M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $7M | |
| Paid-in Capital | $408M | $626M | $541M | $392M | $392M | $317M | $316M | $316M | $315M | $379M | $376M | $376M | $460M | $457M | $456M | $359M | |
| Retained Earnings | $-270M | $-441M | $-393M | $-348M | $-315M | $-313M | $-286M | $-263M | $-233M | $-266M | $-228M | $-211M | $-280M | $-220M | $-203M | $-275M | |
| Treasury Stock | $800.0K | $1M | $834.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $953.0K | $1M | |
| AOCI | $500.0K | $400.0K | $497.0K | $502.0K | $861.0K | $1M | $905.0K | $709.0K | $750.0K | $683.0K | $761.0K | $687.0K | $698.0K | $783.0K | $743.0K | $543.0K | |
| Stockholders' Equity | $160M | $208M | $169M | $53M | $86M | $3M | $27M | $54M | $79M | $112M | $144M | $164M | $179M | $212M | $244M | $82M | |
| Liabilities + Equity | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Shares Outstanding | · | · | · | 136,975,159 | 136,973,697 | 102,858,868 | · | · | · | · | · | · | · | · | · | · |
现金流 8
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $4M | $2M | $2M | $516.0K | $1M | $2M | $-453.0K | $2M | $2M | $2M | $1M | $2M | $2M | $975.0K | $1M | $1M | |
| Operating Cash Flow | $-53M | $-49M | $-35M | $-32M | $-34M | $-20M | $-12M | $-22M | $-35M | $-35M | $-20M | $-26M | $-21M | $-20M | $-10M | $-1M | |
| CapEx | $400.0K | $400.0K | $373.0K | $117.0K | $32.0K | $0 | $-125.0K | $396.0K | $732.0K | $1M | $50.0K | $164.0K | $111.0K | $373.0K | $238.0K | $131.0K | |
| Investing Cash Flow | $-600.0K | $-300.0K | $-715.0K | $-241.0K | $-38.0K | $-400.0K | $793.0K | $-109.0K | $691.0K | $-2M | $-322.0K | $-341.0K | $42.0K | $152.0K | $-229.0K | $11.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $100.0K | $89M | $159M | $130.0K | $117M | $0 | $675.0K | $7.0K | $-33.0K | $-62.0K | $-837.0K | $8M | $-14.0K | $-818.0K | $195M | $-129.0K | |
| Net Change in Cash | $-54M | $35M | $124M | $-33M | $90M | $-20M | $-14M | $-20M | $-35M | $-40M | $-25M | $-18M | $-17M | $-35M | $174M | $-3M | |
| Free Cash Flow | · | $-50M | · | · | · | $-20M | · | · | · | $-36M | · | · | $-21M | · | · | $-2M |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| Net Margin | -7200.0% | -5288.9% | · | -1195.5% | -2858.4% | -3596.2% | · | -2839.7% | -2852.4% | -1943.5% | -705.6% | -1059.6% | -937.1% | -833.5% | -1506.8% | -656.2% | |
| Pretax Margin | -7171.4% | -5266.7% | · | -1195.5% | -2850.4% | -3596.2% | · | -2839.7% | -2852.4% | -1940.1% | -705.6% | -1059.0% | -937.1% | -833.5% | -1506.8% | -652.8% | |
| EBITDA Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| ROA | -27.5% | -30.0% | · | -32.6% | -32.5% | -27.6% | · | -21.5% | -20.0% | -14.4% | -7.6% | -9.7% | -11.7% | -8.2% | -9.5% | -9.9% | |
| ROE | -40.9% | -45.2% | · | -62.1% | -50.7% | -47.3% | · | -30.8% | -27.2% | -18.8% | -9.4% | -11.9% | -15.8% | -10.5% | -11.9% | -13.3% | |
| ROIC | -31.7% | -23.1% | · | -64.8% | -47.8% | -926.5% | · | -56.1% | -42.8% | -25.6% | -12.7% | -15.3% | -11.8% | -8.5% | -9.8% | -20.5% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.8 | · | 1.8 | 2.5 | 0.7 | · | 2.2 | 3.3 | 4.5 | 5.4 | 5.9 | 6.4 | 7.9 | 8.5 | 3.5 | |
| Quick Ratio | 3.2 | 4.4 | · | 1.4 | 2.1 | 0.3 | · | 1.5 | 2.4 | 3.8 | 4.7 | 5.2 | 5.9 | 7.5 | 8.1 | 2.8 |
效率 1
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $6M | · | $6M | $4M | $4M | · | $6M | $7M | $8M | $9M | $8M | $8M | $7M | $4M | $5M | |
| Net Income TTM | $-173M | $-150M | · | $-133M | $-133M | $-118M | · | $-108M | $-101M | $-89M | $-79M | $-85M | $-78M | $-81M | $-94M | $-101M | |
| Market Cap | · | · | · | $1.37B | $1.25B | $701M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -21.0 | -22.7 | · | -8.8 | -7.4 | -5.7 | · | -0.6 | -0.8 | -1.6 | -3.3 | -3.8 | -3.2 | -2.8 | -3.1 | · | |
| P/S | · | · | · | 225.9 | 281.9 | 159.7 | · | · | · | · | · | · | · | · | · | · | |
| P/B | · | · | · | 25.9 | 14.6 | 244.2 | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | · | · | · | 25.9 | 14.6 | 246.7 | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | · | · | · | · | -35.7 | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | · | · | · | · | · | -35.6 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.8% | -4.4% | · | -11.3% | -13.4% | -17.6% | · | -158.6% | -131.1% | -62.1% | -30.5% | -26.6% | -31.1% | -35.9% | -32.4% | · |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $6M | $4M | $16M | $5M | $6M |
| 营业利润率 % | — | — | -486.0% | -1994.9% | -1727.6% |
| 净收入 | $-147M | $-114M | $73M | $96M | $-98M |
| 稀释后每股收益 (EPS) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | — | — | 4.3 | 7.6 | 3.6 |
| 速动比率 | — | — | 3.8 | 7.1 | 2.5 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | — | — | $-80M | $-56M | $-109M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 78 家申报者 · $297.4M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 18 (-11 与上一季度对比) | 10 (0 与上一季度对比) | 14 (+1 与上一季度对比) | 24 (+12 与上一季度对比) | -1.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 10 位内幕人士 · 4 位高管 · 3 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Daniel Tasse | Chief Executive Officer | 2023年11月20日 A | — | 0 | 0 | $0 |
| Virginie Boucinha | Chief Financial Officer | 2023年11月20日 A | 19000 | 0 | 0 | $0 |
| Sebastien Robitaille | Chief Financial Officer | 2022年11月21日 A | 36500 | 0 | 0 | $0 |
| Pharis Mohideen | Chief Medical Officer | 2026年7月29日 S | 144531 | 0 | 1 | $-1253 |
| Timothy E Morris | 董事 | 2023年8月25日 P | 12000 | 0 | 0 | $0 |
| Daniel B Soland | 董事 | 2023年8月1日 P | 20000 | 0 | 0 | $0 |
| Adora Ndu | — | 2021年6月10日 P | — | 0 | 0 | $0 |
| Viviane Monges | — | 2021年6月10日 P | — | 0 | 0 | $0 |
| Madduri Ravin Rao | — | 2021年6月10日 P | — | 0 | 0 | $0 |
| Michel De Rosen | — | 2021年6月10日 P | — | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 2 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×10 申报 | 2026年1月14日 | 9.99% | 修订 | 被动投资 | SEC |
| Bpifrance Participations S.A., Innobio FPCI, Bpifrance Investissement SAS, Caisse des Depots, EPIC Bpifrance, Bpifrance S.A. ×11 申报 | 2026年1月7日 | 4.70% | 修订 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 1 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| APIE · Trust for Professional Managers | 0.00% | 2245 NS | 2026年5月31日 | N-PORT |